Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

SHIFT-IBD: Switching to High-efficacy Anti-IL-23 Guselkumab in Ustekinumab-exposed Persons With Active IBD

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT07245394
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:26.721529+00:00
Published At
2026-02-12T00:00:00+00:00
Record Updated At
2026-02-12
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Inflammatory Bowel Disease (IBD)", "Crohn Disease (CD)", "Ulcerative Colitis (UC)", "IBD-unclassified (IBD-U)"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-02-12"
protocolSection.identificationModule.nctId
"NCT07245394"
protocolSection.identificationModule.officialTitle
"SHIFT-IBD: Switching to High-efficacy Anti-IL-23 Guselkumab in Ustekinumab-exposed Persons With Active IBD"
protocolSection.statusModule.overallStatus
"RECRUITING"
protocolSection.designModule.phases
[]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Inflammatory Bowel Disease (IBD) (protocolSection.conditionsModule.conditions)
  • Crohn Disease (CD) (protocolSection.conditionsModule.conditions)
  • Ulcerative Colitis (UC) (protocolSection.conditionsModule.conditions)
  • IBD-unclassified (IBD-U) (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.